Doctor Heike Schwende

Novartis Pharma AG, Basel (Switzerland)

Follow

Contributor content

Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients

Presentation

Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients

ESC 365 is supported by

novartis

Explore sponsored resources